Sorrento Therapeutics, Inc. To Present At Two Healthcare Conferences
SAN DIEGO, Sept. 5, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, is scheduled to present a corporate overview at two upcoming conferences.
Event: 16th Annual Rodman & Renshaw Global Investment Conference
When: Tuesday, September 9, 2014 at 11:40 AM ET - 12:05 PM ET
Where: Holmes II Salon (4th Floor), New York Palace Hotel, NYC
Event: Aegis Capital 2014 Healthcare and Technology Conference
When: Friday, September 12, 2014 at 1:30 PM PT - 1:55 PM PT
Where: Chopin 2 Room, Encore at the Wynn Hotel, Las Vegas, Nevada
A copy of the presentation will be available on the Company's website at www.sorrentotherapeutics.com.
About Sorrento Therapeutics, Inc.
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bispecific therapeutic antibodies, and ADCs.
This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about commencing its Cynviloq registrational trial; and the advances made in developing human monoclonal antibodies, if any; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2013, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
SOURCE Sorrento Therapeutics, Inc.